Clinical Trial Opportunity for Adults with Stargardt Disease
The clinical trial team at The Retina Clinic London have asked us to share an opportunity to participate in a Phase 1 clinical trial for AAVB 039 for Stargardt Disease.
Search
Search results
Ocugen announce Phase 3 enrolment completion for OCU400, the largest gene agnostic therapy trial for RP
Biotechnology company Ocugen has announced the enrolment completion of their phase 3 clinical trial for OCU400.
Atsena Therapeutics present positive clinical data for XLRS gene therapy program
Promising early clinical trial results suggest that ATSN-201, an investigational gene therapy for X-linked retinoschisis (XLRS), could offer a potential new treatment approach for this rate inherited retinal condition.
RECORDING: Annual Conference – 28 September 2024
A recording of the Retina UK Annual Conference on 28 September 2024. The Conference was held at the Pendulum Hotel in Manchester and online.
The UK Inherited Retinal Dystrophy Consortium
In 2014 we funded an exciting new collaborative project. The UK Inherited Retinal Dystrophy Consortium (UKIRDC) Project brought together the four largest research groups in the UK specialising in inherited retinal diseases (IRDs).
e-Newsletter May 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Frequently asked questions
These are some of the most commonly asked questions about genetic testing and counselling.
Frequently asked questions
These frequently asked questions should provide a response for most of the queries you might raise.
Your donations make progress possible
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
e-Newsletter – May 2023
Our monthly e-Newsletter featuring the latest updates from Retina UK. Subscribe now to receive these updates directly to your email.